Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Abstract: Provided herein are compounds of formula (1): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Abstract: The present invention relates to indole carboxamide compounds of formula (I) or a salt thereof wherein R2, R3, R4, R6, R7, R8, R51 and R52 have the meanings as indicated herein, and are MT1 and/or MT2 receptor agonists useful for treating and/or preventing urological diseases.

Abstract: The present invention relates to indole carboxamide compounds of formula (I) or a salt thereof wherein R2, R3, R4, R6, R7, R8, R51 and R52 have the meanings as indicated herein, and are MT1 and/or MT2 receptor agonists useful for treating and/or preventing urological diseases.

Abstract: [Problem] To provided a compound which is useful as an MT1 and/or MT2 receptor agonist. [Means for Solution] The present inventors have conducted studies on MT1 and/or MT2 receptor agonists, and have found that an indole carboxamide compound has an MT1 and/or MT2 receptor agonistic action, thereby completing the present invention. The indole carboxamide compound of the present invention has the MT1 and/or MT2 receptor agonistic action as well as a low CNS penetration, and therefore, it can be used as an agent for preventing and/or treating urological diseases; in one embodiment, lower urinary tract symptoms; in another embodiment, urine storage symptom, in another embodiment, urinary incontinence; in a still another embodiment, stress urinary incontinence; and the like.

Abstract: An exhaust gas purification system comprises a NOx catalyst for absorbing the NOx in the exhaust gas when the air-fuel ratio of the influent exhaust gas is lean and purifying by reducing the absorbed NOx with a reducing agent in the exhaust gas when the air-fuel ratio of the exhaust gas turns rich, a first unit for calculating the amount of NOx absorbed per unit time in each area of the NOx catalyst when the air-fuel ratio of the exhaust gas flowing into the NOx catalyst is lean, and a second unit for calculating the total amount of NOx absorbed into the NOx catalyst by totaling the amounts of NOx calculated by the first calculation unit for the areas of the NOx catalyst.

Abstract: An exhaust gas purification system comprises a NOx catalyst for absorbing the NOx in the exhaust gas when the air-fuel ratio of the influent exhaust gas is lean and purifying by reducing the absorbed NOx with a reducing agent in the exhaust gas when the air-fuel ratio of the exhaust gas turns rich, a first unit for calculating the amount of NOx absorbed per unit time in each area of the NOx catalyst when the air-fuel ratio of the exhaust gas flowing into the NOx catalyst is lean, and a second unit for calculating the total amount of NOx absorbed into the NOx catalyst by totaling the amounts of NOx calculated by the first calculation unit for the areas of the NOx catalyst.